Changes to the outlook for researcher-initiated gene therapies in Japan should help bring significant advances to important work, say experts.
Focal Point |
Genome editing and gene therapy in Japan
Japan’s gene therapy and genome editing boom
The timing is right, as intensified commercial interest collides with maturing research in these cutting-edge fields.
Focal Point feature
Pentatricopeptide repeat (PPR) technology can precisely edit Both RNA and DNA. Free of CRISPR’s intellectual property mire, this system could revolutionize gene therapy.
Target-AID, a new mutagenesis-based gene-editing tool, opens the door to modified microbes, and a revolution in microbiome therapies.
Mitsubishi Tanabe Pharma Corporation has invested in cutting-edge gene therapy projects for critical limb ischaemia and haemophilia B, as well as a bold new research facility.
A long history of research on safe and efficient delivery has put Jichi Medical University at the centre of a number of important gene-therapy clinical trials for neurological disorders.